Latest Articles
-
Merck Continues To Disappoint As Weakness In Januvia’s Sales & Japanese Market Adds To Its Woes
Merck ‘s (NYSE:MRK) shares fell slightly on weak Q3 2013 earnings. The company’s revenue growth is under severe pressure due to the continued impact of the loss of patent exclusivity of certain key drugs, adverse currency movements an...
-
Bristol-Myers Earnings: New Drugs Drive Results, Eliquis Gaining Traction
Bristol-Myers Squibb (NYSE:BMY) reported its Q3 earnings on October 23. In the last few quarters, the drug maker’s top line has been impacted by the patent expiry of Plavix and Avapro/Avalide, two major cardiovascular drugs. However, it swung bac...
-
Merck Earnings Preview: Competition From Generics & Currency Movements Will Continue To Plague Merck
Merck (NYSE:MRK) will release its Q3 2013 earnings on October 28, and the results will reflect the impact of growing competition and adverse currency movements. On a broader level, the company is facing similar problems as the rest of the pharmac...
-
Gold Prices Still Dependant On The US Dollar
Submitted by SK Options Trading as part of our contributors program . Gold Prices Still Dependant On The US Dollar Background We will begin by taking a look at some of the factors that usually drive investors into the arms of safe haven...
-
Bristol-Myers Earnings Preview: New Drugs To Maintain Growth
Bristol-Myers Squibb (NYSE:BMY) is scheduled to report its earnings for Q3 2013 on October 23. Last quarter, the company reported a 9% year-on-year decline in its revenue. However, the decline was primarily due to the U.S. patent expiries of Ava...
-
Oncology Drugs Drive Roche’s Revenue, Full Year Outlook Confirmed
Roche Holdings AG (PINK:RHHBY) reported its third quarter sales figures on October 17, disclosing that revenues for the first nine months of 2013 were 34.9 billion Swiss francs, an increase of 6% year-on-year (y-o-y) at constant exchange rates. F...
-
Merck’s Job Cuts Highlight A Big Problem Facing Big Pharma Companies
Merck (NYSE:MRK) has announced that it will cut its workforce by 20% over the next two years, which could result in the loss of close to 16,000 jobs. This will leave the company with less than 65,000 employees which is in stark contrast to its pe...
-
Biotech Merger And Acquisition Rumors And News
Submitted by Scott Matusow as part of our contributors program . Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. However, there is no way to know for sure since I am not an insider and have n...
-
AcelRx May Be In Play For Acquisition Soon: NDA To Be Filed At Month’s End
Submitted by Scott Matusow as part of our contributors program . We believe that AcelRx Pharmaceuticals (NASDAQ: ACRX) warrants a close look by both longer-term investors and shorter-term catalyst traders. We have been hearing some strong...
-
Is There Much Hope For Merck In Alzheimer Drug Clinical Trials?
Recent efforts for developing effective Alzheimer drugs haven’t been successful. Yet, Merck (NYSE:MRK) hopes to do something different with its BACE Inhibitor, MK-8931. The company presented phase 1 clinical trial data in July, which sugges...
-
100 Mostly Acquired Corporate Stocks By Stock Market Pros
Submitted by Dividend Yield as part of our contributors program . 100 most bought stocks by investment professionals originally published on Dividend Yield ? Stock, Capital, Investment . Big investors are sometimes better informed about the is...
-
Januvia’s Performance Raises Concerns For Merck
Merck (NYSE:MRK) has been struggling for the past few quarters due to the loss of exclusivity of certain key drugs including Singulair, competition from generics and the negative impact of currency movements. To revive its growth, the company is ...
-
Wedbush Expert Declares Money for Biotech Is Still Out There
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (8/8/13) The bull market in biotech stocks is coming up on its two-year anniversary, and l...
-
Merck Suffers From Generic Competition And A Stronger Dollar
Merck ‘s (NYSE:MRK) revenues slumped by 11% in Q2 2013 due to the loss of exclusivity of certain key drugs including Singulair, competition from generics and the negative impact of currency movement. The company’s results reflected si...
-
Merck Earnings: Patent Losses Will Continue To Dampen Growth
Merck (NYSE:MRK) will release its Q2 2013 earnings on July 30 and like its counterpart Pfizer (NYSE:PFE), its results will reflect the negative impacts of patent expiry of big drugs and adverse currency movements. The company’s revenues de...
